TW436474B - Process for the preparation of isopropyl-methyl-[2-(3-n-propoxyphenoxy)ethyl]amine - Google Patents
Process for the preparation of isopropyl-methyl-[2-(3-n-propoxyphenoxy)ethyl]amine Download PDFInfo
- Publication number
- TW436474B TW436474B TW087120435A TW87120435A TW436474B TW 436474 B TW436474 B TW 436474B TW 087120435 A TW087120435 A TW 087120435A TW 87120435 A TW87120435 A TW 87120435A TW 436474 B TW436474 B TW 436474B
- Authority
- TW
- Taiwan
- Prior art keywords
- patent application
- scope
- item
- ethyl
- amine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Anesthesiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
4 3 647 4 五、發明說明(1) 發明範圍 本發明係關於一種合成異丙基-曱基-[2-(3 -正-丙氧基 苯氧基)乙基]胺之新穎方法。再者,本發明亦係關於一種 新穎中間物,及該方法中視需要選用之純化步驟。此外, 本發明亦係關於含異丙基-曱基-[2-(3 -正-丙氧基苯氧基) 乙基]胺之醫藥調配物之製法,及異丙基-曱基-[2-(3 -正-丙氧基苯氧基)乙基]胺在醫學上之應用。 發明背景與先前技藝 異丙基-甲基-[2-(3 -正-丙氧基苯氧基)乙基]胺是一種 具有麻醉性質之化合物。其可作為治療疼痛(包括局部性 疼痛,且尤其發生在無傷的皮膚上之疼痛)之局部用局部 麻醉藥。 W0 9715548揭示一製備異丙基-曱基-[2-(3 -正-丙氧基 苯氧基)乙基]胺之方法。該方法包括數個步驟:先使3 -正 -丙氧基紛與1,2 -二>臭乙烧反應5產生1-(2 - >臭乙氧基)-3-正-丙氧基苯。接著,在墨熱器内,使1-(2 -ΐ臭乙氧基)-3-正-丙氧基苯與N-曱基異丙胺反應。接著經由真空蒸餾進 一步使該產物,異丙基-曱基-[_2-(3_正-丙氧基苯氧基)乙 基]胺純化。 發明摘述 本發明之目的係提供一種適於大規模製造之製備異丙基 -甲基-[2-(3 -正-丙氧基苯氧基)乙基]胺之新方法。 以下流程圖係說明在製備異丙基-甲基-[2 - ( 3 -正-丙氧 基苯氧基)乙基]胺時,以3-丙氧基酚開始反應之主要反應4 3 647 4 V. Description of the invention (1) Scope of the invention The present invention relates to a novel method for synthesizing isopropyl-fluorenyl- [2- (3--n-propoxyphenoxy) ethyl] amine. Furthermore, the present invention also relates to a novel intermediate and a purification step optionally used in the method. In addition, the present invention also relates to a method for preparing a pharmaceutical formulation containing isopropyl-fluorenyl- [2- (3--n-propoxyphenoxy) ethyl] amine, and isopropyl-fluorenyl- [ Application of 2- (3-n-propoxyphenoxy) ethyl] amine in medicine. Background and Prior Art Isopropyl-methyl- [2- (3--n-propoxyphenoxy) ethyl] amine is a compound with narcotic properties. It can be used as a topical anesthetic for the treatment of pain, including localized pain, and especially pain on non-injured skin. WO 9715548 discloses a method for preparing isopropyl-fluorenyl- [2- (3--n-propoxyphenoxy) ethyl] amine. The method includes several steps: firstly reacting 3 -n-propoxy group with 1,2-di > styrosine to produce 1- (2-> styethoxy) -3-n-propoxyl Benzene. Next, in an ink heater, 1- (2-dihydroxyethoxy) -3-n-propoxybenzene was reacted with N-fluorenylisopropylamine. The product was then further purified by vacuum distillation, isopropyl-fluorenyl-[_ 2- (3-n-propoxyphenoxy) ethyl] amine. SUMMARY OF THE INVENTION The object of the present invention is to provide a new method for preparing isopropyl-methyl- [2- (3--n-propoxyphenoxy) ethyl] amine suitable for large-scale manufacturing. The following flow chart illustrates the main reaction that starts with 3-propoxyphenol when preparing isopropyl-methyl- [2-(3--n-propoxyphenoxy) ethyl] amine.
d 3 6 4 7 4 ’ 五、發明說明(2) 步驟D所使用之起始物質以及各反應物很容易由本技藝已 知之方法獲得。d 3 6 4 7 4 ′ 5. Description of the invention (2) The starting materials and reactants used in step D can be easily obtained by methods known in the art.
Scheme 1 Step 1Scheme 1 Step 1
XTXT
Ethylene carbonate, solid-liquid phase-transfer catalysis XT (1)Ethylene carbonate, solid-liquid phase-transfer catalysis XT (1)
、OH, OH
Step 2Step 2
、〇H halogenating or sulphonating reagent, 〇H halogenating or sulphonating reagent
XT ⑴ (2) :鹵素或績酸酯XT ⑴ (2): halogen or ester
Step 3 χτ。〜χ (2} x=鹵素或績酸醋Step 3 χτ. ~ Χ (2) x = halogen or vinegar
IsopropyiamineIsopropyiamine
〇、〇,
NHNH
Hi 第6頁 d3647 4 五、發明說明(3)Hi Page 6 d3647 4 V. Description of the Invention (3)
Step 4Step 4
Formaldehyde, H2 metal catalyst (3)Formaldehyde, H2 metal catalyst (3)
(4) 本發明之改良方法之優點在下文各段中有揭示。(4) The advantages of the improved method of the present invention are disclosed in the following paragraphs.
本發明另一項目的為'提供一種使用具環境親和性之試劑 與溶劑之方法。醫藥工業内及外之環境團體對於該工業應 該發展並使用具環境親和性之方法具有普遍興趣。本發明 之方法並未使用任何在根據先前技藝之方法中所使用之致 突變烷化劑,例如1,2 -二溴乙烷。因此,本發明其中一項 目的係提供一種製備異丙基-甲基-[2-(3 -正-丙氧基苯氧 基)乙基]胺之方法,其中可不必使用1,2 -二溴乙烷。1,2 -二溴乙烷是一種已知致突變化合物,因此,可能的話,其 使用應該受到限制。在大規模製造時,尤其儘可能避免使 用。 本發明另一項目的係提供一種使粗異丙基-甲基-[2-( 3-正-丙氧基苯氧基)乙基]胺純化之新穎且視需要選用之方 法。令人驚訝的是,我們頃發現異丙基-甲基-[2 - ( 3 -正-丙氧基苯氧基)乙基]胺之單磷酸鹽是一種結晶狀化合物。 該選用純化步驟在流程圖2中有表示。Another aspect of the present invention is to provide a method for using environmentally friendly reagents and solvents. Environmental groups within and outside the pharmaceutical industry have a general interest in ways in which the industry should develop and make appliances environmentally friendly. The method of the present invention does not use any mutagenic alkylating agents used in methods according to the prior art, such as 1,2-dibromoethane. Therefore, one of the objects of the present invention is to provide a method for preparing isopropyl-methyl- [2- (3--n-propoxyphenoxy) ethyl] amine, in which the use of 1, 2-di Ethyl bromide. 1,2-Dibromoethane is a known mutagenic compound, so its use should be limited if possible. It is especially to be avoided in mass production. Another item of the present invention is to provide a novel and optional method for purifying crude isopropyl-methyl- [2- (3-n-propoxyphenoxy) ethyl] amine. Surprisingly, we have found that isopropyl-methyl- [2- (3-n-propoxyphenoxy) ethyl] amine monophosphate is a crystalline compound. This optional purification step is shown in Scheme 2.
第7頁 436474 五、發明說明(4) Scheme 2 h3po4Page 7 436474 V. Description of the invention (4) Scheme 2 h3po4
(4) 〇、(4) 〇,
XTXT
Base (5) 在v驟1巾使用固體〜液體相轉移 基酿與碳酸乙二醇反應 匕條件,估 該反應。該反應較佳ϋ J佳於60 —1 20 °CT,長^孰 劑或二甲苯)中進二此劑(例如,非質子1生有1進行 (但不限於)DMF,及卜甲 貝子性有機溶質之實 '溶 =為較佳非質子性有機溶劑 甲基〜: 觸媒座生該固體-液體相〜轉移催侔_株嶮與相轉 觸媒之用量並不嚴格要求,因此可=件。该驗與相〜轉牙 而不同。該鹼與相-轉移觸媒可以3以根據本技藝已知程· 生固體-液體相-轉移催化條件之、南 疋力任何本技藝已知可, 合之驗管·你丨句.括(但不rr m~驗'與相-轉敕fee &Base (5) In v1, use solid to liquid phase transfer. The reaction between base and ethylene carbonate was used to estimate the reaction. The reaction is better: J is better than 60-1 20 ° CT, long tincture or xylene). This agent (for example, aproton 1 has 1 and 1 is carried out (but not limited to) DMF, and pupa shellfish). Organic solute 'Solution = is the preferred aprotic organic solvent methyl ~: The catalyst base generates the solid-liquid phase ~ Transfer catalyst_Strain and the amount of phase transfer catalyst is not strictly required, so it can be = This test is different from phase to tooth rotation. The alkali and phase-transfer catalyst can be produced in accordance with the known conditions of this technology. The solid-liquid phase-transfer catalyst conditions can be generated. , 合 之 测 管 · 你 丨 句. Includes (but not rr m ~ Experience 'and phase-turned fee &
”溶劑以進行該反應。碳酸乙二醇用佐何領外 當莖,較佳為2-3當量。使用固 二用夏為K 產生該固體-液體相〜轉移催化侔件岭與相轉, 士成喜* 丁辟功上、因此π條件。该鹼與相〜轉考 適合之鹼實例 相-轉移催化條件>λ1何本技藝已知可"The solvent is used to carry out the reaction. The terephthalate is used as the ethylene carbonate, preferably 2-3 equivalents. The solid-liquid phase is produced by using solid secondary Xia ~ K ~ transfer catalyzed ridges and phase inversion, Shi Chengxi * Ding Pi Gong, therefore π conditions. The base and the phase ~ suitable base examples for phase-transfer catalysis conditions > λ1 is known in the art
1千之適合鹼血栩-絲 J ^ Λ J包括(但不限於)碳酸 二相&轉移觸媒 及碳酸氫鉀。碳酸鉀為‘較佳鹼^人’故酸氫納’碳§丨 〇之相_轉移觸媒實One thousand suitable alkalemia-filament J ^ Λ J includes (but is not limited to) carbonate biphasic & transfer catalyst and potassium bicarbonate. Potassium carbonate is the phase of ‘better alkali ^ human’ sodium hydrogen acid ’carbon § 丨 〇 _ transfer catalyst
43 64 7 4 五、發明說明¢5) 包括(但不限於)四丁銨化碘,四丁基硫酸氫銨,及四丁銨 化溴。四丁銨化溴為較佳相-轉移觸媒。 步驟1中所使用之相-轉移觸媒可以被於步驟1所使用之 條件下,具有可作為相-轉移觸媒之固有性質之化合物取 代。此種化合物之實例包括(但不限於)聚乙二醇(PEG), 例如,PEG 60 00。 完全反應後,使反應混合物冷卻,經水稀釋,然後經適 合之有機溶劑(例如,二曱苯或曱基第三-丁醚)萃取。濃 縮該有機相,且經由蒸德使該粗2 - ( 3 -丙氧基-苯氧基)-乙 醇純化。 在步驟2中,進一步使上述步驟1中所形成之2-(3-丙氧 基-苯氧基)-乙醇與適合之試劑反應以產生式2化合物,43 64 7 4 V. Description of the invention ¢ 5) Including (but not limited to) tetrabutylammonium iodide, tetrabutylammonium hydrogen sulfate, and tetrabutylammonium bromide. Tetrabutylammonium bromide is the preferred phase-transfer catalyst. The phase-transfer catalyst used in step 1 may be replaced by a compound having inherent properties that can be used as the phase-transfer catalyst under the conditions used in step 1. Examples of such compounds include, but are not limited to, polyethylene glycol (PEG), such as PEG 60 00. After the reaction is complete, the reaction mixture is cooled, diluted with water, and then extracted with a suitable organic solvent (e.g., diphenylbenzene or fluorenyl tertiary-butyl ether). The organic phase was concentrated and the crude 2- (3-propoxy-phenoxy) -ethanol was purified via distillation. In step 2, the 2- (3-propoxy-phenoxy) -ethanol formed in the above step 1 is further reacted with a suitable reagent to produce a compound of formula 2,
(2) 其中X是溴,氯,碘或磺酸酯基圑'。磺酸酯之實例包括(但 不限於)烷烴-與芳基磺酸酯,例如,甲基磺酸酯,乙基磺 酸醋,對-甲苯績酸i旨,對-漠苯基橫酸S旨。較佳之式2化 令物為磺酸酯。能夠產生較佳之式2化合物之試劑實例包 括(但不限於)曱基磺醯氯,乙基磺醯氯,對-曱苯磺醯氣 及對~溴磺醯氯。 在步驟3中,進一步在水存在下,使式2化合物之有機溶 劑(例如,曱基第三-丁醚或曱苯)與異丙胺反應。較佳於(2) where X is bromine, chlorine, iodine or sulfonate hydrazone '. Examples of sulfonates include, but are not limited to, alkane- and aryl sulfonates, such as, for example, methanesulfonate, ethylsulfonate, p-toluene acid, p-mophenyl phenylsulfonic acid S Purpose. A preferred formula 2 is a sulfonate. Examples of reagents capable of producing preferred compounds of formula 2 include, but are not limited to, sulfenylsulfonium chloride, ethylsulfonylsulfonium chloride, p-fluorenylsulfonium chloride, and p-bromosulfonyl chloride. In step 3, an organic solvent (e.g., fluorenyl tertiary-butyl ether or toluene) of the compound of Formula 2 is further reacted with isopropylamine in the presence of water. Better than
43647 4 五、發明說明(6) 高溫(較佳60-1 10°C)下,長時間並在高壓(較佳卜10大氣 壓)下進行該反應。應該以過量(例如,2至6當量,較佳 3當量)添加異丙胺。視需要可添加額外且非—親核性驗 (例如’碳酸鉀或碳酸鈉)至該反應混合物中。 該反應混.合物中含有之水量並未嚴格規定,且可以視需 要忽略。接著’使反應混合物冷卻,然後以激烈授拌添加 水性酸’直到該水性相之pH達到3 — 5 (較佳3_3 . 5 )恆值^止 。分離該水性相,經曱基第三_ 丁醚或甲苯洗滌,其後, 不需任何進一步純化’即可在後續步驟中使用。 在步驟4中,於鈀在木炭上之存在下,使上述步驟3中所 製成之異丙基_甲基-[2-(3-正-丙氧基苯氧基)乙基]胺與 甲醛反應。於(或高於)大氣壓力(例如,1 _ 6巴)下使該反 ,混合物氫化數小時。雖然甲醛之用量並未嚴格規定,但 疋可^以在1 - 1 〇當量之間。鈀在木炭之上使用量為〇 . 〇 1至 .5莫耳畲量,較佳為〇, 〇5_〇. 2。其後,該反應混合物經 水性,(例如,氫氧化鈉)處理至PH〜12,然後經甲基第三_ 1醚萃取。分離該有機相,並經蒸餾產生純異丙基—甲基 正-丙氧基苯氧基)乙基]胺。 V人驚冴的是,我們已經能夠自步驟4之反應混合物使 =丙基-甲基-[2-(3 -正-丙氧基苯氧基)乙基]胺結晶化以 ,^成對應單磷酸鹽。該異丙基—甲基—[2_(3_正_丙氧基 苯氧基)乙基]胺之單磷酸鹽是一種異丙基—曱基-[2_(3_正 -丙氧基苯氧基)乙基]胺之結晶狀且具安定性之鹽,因此 ’、有有;〖生。較佳在製備異丙基__甲基一 正—丙氧43647 4 V. Description of the invention (6) The reaction is carried out under high temperature (preferably 60-1 10 ° C) for a long time and under high pressure (preferably 10 atmospheric pressure). Isopropylamine should be added in excess (for example, 2 to 6 equivalents, preferably 3 equivalents). Additional and non-nucleophilic tests (e.g., 'potassium carbonate or sodium carbonate) can be added to the reaction mixture as needed. The amount of water contained in the reaction mixture is not strictly regulated and can be ignored as needed. Then "the reaction mixture is cooled, and then the aqueous acid is added with vigorous stirring" until the pH of the aqueous phase reaches a constant value of 3-5 (preferably 3-3.5). The aqueous phase was separated and washed with fluorenyl tertiary-butyl ether or toluene, after which it was used in subsequent steps without any further purification '. In step 4, in the presence of palladium on charcoal, the isopropyl_methyl- [2- (3-n-propoxyphenoxy) ethyl] amine prepared in the above step 3 and Formaldehyde reaction. The reaction is hydrogenated at (or higher) atmospheric pressure (for example, 1-6 bar) and the mixture is hydrogenated for several hours. Although the amount of formaldehyde is not strictly regulated, it can be between 1 and 10 equivalents. Palladium is used on charcoal in an amount of from 0.01 to .5 mol, preferably from 0.05 to 0.2. Thereafter, the reaction mixture is treated with water, (for example, sodium hydroxide) to a pH of ~ 12, and then extracted with methyl tertiary ether. The organic phase was separated and distilled to give pure isopropyl-methyl-n-propoxyphenoxy) ethyl] amine. People are surprised that we have been able to crystallize = propyl-methyl- [2- (3--n-propoxyphenoxy) ethyl] amine from the reaction mixture of step 4 to the corresponding Monophosphate. The isophosphate-methyl- [2_ (3_n-propoxyphenoxy) ethyl] amine monophosphate is an isopropyl-fluorenyl- [2_ (3_n-propoxybenzene Oxy) ethyl] amine is a crystalline and stable salt, so ', you have; Isopropyl-methyl-n-propoxylate
第10頁 436474 五、發明說明(7) 基苯氧基)乙基]胺之方法中導入結晶狀中間物。其 < 以在 反應流程中導入簡單且方便的視需要選用之額外純化步驟 ,其中全部中間物為糖漿。因此,根據先前技藝之方法所 使用之耗時間與耗能源蒸餾步驟可以省略。異丙基-曱基 -[2-(3 -正-丙氧基苯氧基)乙基]胺之單碟酸鹽經純化可產 生高純度中間物’其可進一步經由簡單驗化步骤轉化成鮮 應異丙基-甲基-[2-(3~正-丙氧基苯氧基)乙基]胺。 在該選用純化步驟中,先驗定粗異丙基-甲基一 [2-(3〜正 -丙氧基苯氧基)乙基]胺之醋酸乙酯溶液含量,然後調整 成每克上述步驟4中所製成之粗異丙基-曱基-[2-(3 -正-丙 氧基苯氧基)乙基]胺之6-10毫升醋酸乙酯。該異丙基-曱 基-[2-(3 -正-丙氧基苯氧基)乙基]胺之醋酸乙酯溶液含量 較佳為每克異丙基-甲基-[2-(3 -正-丙氧基苯氧基)乙基] 胺之7-9毫升醋酸乙酯。添加甲醇,與磷酸之曱醇溶液至 該異丙基-甲基-[2-(3 -正-丙氧基苯氧基)乙基]胺之已驗 定溶液中。碟酸之用量應該約0. 9至1. 〇莫耳當量,較佳 0. 9 5當量。該已驗定溶液之曱醇總添加量應該調整至與磷 酸使用量相等。所形成異丙基-甲基-[2-(3 -正-丙氧基苯 氧基)乙基]胺之甲醇與醋酸乙酯混合物溶液中之磷酸濃度 應該約5-1 5體積%,較佳9-1 1體積%。經由’例如,過濾法 或離心法收集已沈殿之鹽,然後經醋酸乙酯洗滌。 然後,使上述步驟製成之異丙基-甲基-[2-(3-正-丙氧 基笨氧基)乙基]胺之單磷酸鹽與水混合’接著添加氫氧化 鈉水溶液調整pH至〜11.5。添加曱基第三-丁醚,或其它適Page 10 436474 V. Description of the invention In the method of (7) ylphenoxy) ethyl] amine, a crystalline intermediate is introduced. It is < an additional purification step that is simple and convenient to introduce into the reaction process as needed, where all intermediates are syrup. Therefore, the time-consuming and energy-consuming distillation steps used in the method according to the prior art can be omitted. Isopropyl-fluorenyl- [2- (3--n-propoxyphenoxy) ethyl] amine mono-disc salt can be purified to produce high-purity intermediates, which can be further converted into Xingying isopropyl-methyl- [2- (3 ~ n-propoxyphenoxy) ethyl] amine. In this optional purification step, the content of the ethyl acetate solution of crude isopropyl-methyl- [2- (3 ~ n-propoxyphenoxy) ethyl] amine is tested first, and then adjusted to the above amount per gram. 6-10 ml of ethyl acetate of the crude isopropyl-fluorenyl- [2- (3--n-propoxyphenoxy) ethyl] amine prepared in step 4. The content of the isopropyl-fluorenyl- [2- (3--n-propoxyphenoxy) ethyl] amine in ethyl acetate is preferably per isopropyl-methyl- [2- (3 -N-propoxyphenoxy) ethyl] amine in 7-9 ml of ethyl acetate. Methanol and a methanolic solution of phosphoric acid were added to the tested solution of the isopropyl-methyl- [2- (3--n-propoxyphenoxy) ethyl] amine. The amount of dish acid should be about 0.9 to 1.0 mole equivalent, preferably 0.95 equivalent. The total amount of methanol in the tested solution should be adjusted to be equal to the amount of phosphoric acid used. The concentration of phosphoric acid in the mixture of isopropyl-methyl- [2- (3--n-propoxyphenoxy) ethyl] amine in methanol and ethyl acetate should be about 5-15% by volume, Good 9-1 1% by volume. The precipitated salt is collected via 'e.g., filtration or centrifugation, and then washed with ethyl acetate. Then, the isophosphate-methyl- [2- (3-n-propoxybenzyloxy) ethyl] amine monophosphate prepared in the above step is mixed with water, and then an aqueous sodium hydroxide solution is added to adjust the pH To ~ 11.5. Add fluorenyl tertiary-butyl ether, or other suitable
43 64 7 4 五、發明說明(8) 合溶劑’然後分離雙相。該有機相經水洗滌,並經濃縮’ 產生純異丙基-曱基-[2-(3 -正-丙氧基苯氧基)乙基]胺。 經由上述步驟4製成之粗異丙基-甲基-[2-(3~正-丙氧基 苯氧基)乙基]胺之最終蒸步驟可以由選用純化步驟取代’ 亦即異丙基-曱基-[2-(3 -正-丙氧基苯氧基)乙基]胺之製 備。在此等情況下,較佳以醋酸乙酯取代甲基第三-丁醚 ’萃取該含有粗異丙基-甲基-[2-(3-正-丙氧基苯氧基)乙 基]胺之驗性水性相。其後,經由鹼化步驟使製成之異丙 基-甲基-[2-(3~正-丙氧基苯氧基)乙基]胺之單磷酸鹽轉 化成對應異丙基〜曱基_ [2_(3-正-丙氧基苯氧基)乙基]胺 。該程序模式可輕易地由技師完成。 在以下非限制性實例中’更詳述本發明。可參考流程圖 1與2之羅馬數字。 實例 實例1 (2-(3-丙氧基-苯氧基乙醇(1) 添加礙酸乙二醇(20. 7千克,234. 8莫耳),K2C03(17. 9千 克,126.7莫耳),四丁銨化溴(3·8千克,1〗.5莫耳)及 卜曱基-2-¾咯啶酮(565升)至3_丙氧基酚(179千克, 11 7 · 4莫耳)中。使該混合物加熱至約9 0。〇約〗〇小時,然後 冷卻至45 °C ’接著先後添加水(1 32升)與甲基第三—丁喊 (8 2升)°分離各相,接著,先後以0· 5 M HC1 (水溶液)與 〇· 5 M NaHCO〆水溶液)洗滌有機相。利用減壓濃縮有機 相’然後經由蒸餾(1 5 0 °C / 0 · 9 5兆巴)純化該粗產物i,產43 64 7 4 V. Description of the invention (8) Solvent solvent 'Then the two phases are separated. The organic phase was washed with water and concentrated 'to give pure isopropyl-fluorenyl- [2- (3--n-propoxyphenoxy) ethyl] amine. The final distillation step of the crude isopropyl-methyl- [2- (3 ~ n-propoxyphenoxy) ethyl] amine prepared through the above step 4 can be replaced by an optional purification step, that is, isopropyl Preparation of fluorenyl- [2- (3--n-propoxyphenoxy) ethyl] amine. In these cases, it is preferable to extract the methyl isopropyl-methyl- [2- (3-n-propoxyphenoxy) ethyl group] with ethyl acetate instead of methyl tert-butyl ether '. Aqueous aqueous phase of amine. Thereafter, the prepared isopropyl-methyl- [2- (3 ~ n-propoxyphenoxy) ethyl] amine monophosphate was converted into the corresponding isopropyl ~ fluorenyl group through the alkalizing step. [2_ (3-n-propoxyphenoxy) ethyl] amine. This program mode can be easily completed by a technician. The invention is described in more detail in the following non-limiting examples. Please refer to the Roman numerals in flowcharts 1 and 2. Examples Example 1 (2- (3-propoxy-phenoxyethanol (1) with ethylene glycol (20.7 kg, 234.8 moles), K2C03 (17.9 kg, 126.7 moles) , Tetrabutylammonium bromide (3.8 kg, 1.5 moles) and buprof-2--2-pyrrolidone (565 liters) to 3-propoxyphenol (179 kg, 11 7 · 4 moles) The mixture was heated to about 90 ° C. for about 0 hours, then cooled to 45 ° C. Then water (130 liters) and methyl tertiary-butane (82 liters) were added successively to separate the phases. Then, the organic phase was washed successively with 0.5 M HC1 (aqueous solution) and 0.5 M NaHCO (aqueous solution). The organic phase was concentrated under reduced pressure and then distilled (1 50 ° C / 0 · 9 5 MPa). The crude product i is purified to yield
第12頁 436474 五、發明說明(9) 生層析純度超過97%如油狀物之〖(I? 9千克)。 MS (EI) : 196 (34) ’ 153 (13),152 (7),135 (4), 111 (67) ’110 (100)NMR (20 0 MHz) : 5 7.15 (t, 1H) ’6.5 Cm,3H),4.〇 (m,2H),3.9 (m, 4H),2.5 (s,1 Η),1. 7 9 (m,2 Η),1. (t,3 Η )。 13C NMR (50 MHz) : 5 160.4,159.8 ’129.9,107.2, 106.7 ’101,6 ’69.5,69.2,61.4,22.6,10.5。 曱基石黃酸3-丙氧基-苯氧基乙輯(2) 使1(17.9千克’91.0莫耳)已溶解在甲基第三-丁醚(83 升)與三己胺(15.2升’1〇 8.1莫耳)中之溶液與Msci (7.7 升,99. 1 2莫耳)反應。於環境溫度下使所形成漿體靜置約 2小時’添加水,分離各相,然後在後續步驟中使用該有 機相。 MS (El) :274 (55) ’232 (7) ,195 ⑴,153 (6), 135 (16) ,123 (100) ,11〇 (66) ,79 (64)。 異丙基_[2-(3-丙乳基-苯氧基)-乙基]-胺(3) 添加K2C03 (14.0千克’98.1莫耳),異丙胺(36. 2升’ 4 5 5 · 9莫耳)及水(31升)至名之溶液中。將反應器密封,使 該混合物加熱至9 0 °C 1 6小時,產生約2巴壓力。使該反應 渴》合物冷卻至壤境溫度’將水性相棄置,且有機相經水洗 滌。添加0 5 M HgSO4 (水溶液)至該有機相内以使pH達 ~ 3. 5 ’然後分離各相。以曱基第三-丁趟洗條該水性相, 並在後續步驟中使用該水性相。 MS (El) :237 (7) ,222 (34) ,194 ⑴,135 ⑺,Page 12 436474 V. Description of the invention (9) The purity of the biochromatography is more than 97% (such as I (9 kg)). MS (EI): 196 (34) '153 (13), 152 (7), 135 (4), 111 (67)' 110 (100) NMR (20 0 MHz): 5 7.15 (t, 1H) '6.5 Cm, 3H), 4.0 (m, 2H), 3.9 (m, 4H), 2.5 (s, 1 Η), 1. 7 9 (m, 2 Η), 1. (t, 3 Η). 13C NMR (50 MHz): 5 160.4, 159.8 '129.9, 107.2, 106.7' 101, 6 '69.5, 69.2, 61.4, 22.6, 10.5. Pyridoxine 3-propoxy-phenoxyacetate (2) makes 1 (17.9 kg '91 .0 mol) dissolved in methyl tertiary-butyl ether (83 liters) and trihexylamine (15.2 liters) The solution in 10.8 Molar) was reacted with Msci (7.7 liters, 99.12 Molar). The formed slurry was allowed to stand at ambient temperature for about 2 hours', water was added, the phases were separated, and then the organic phase was used in a subsequent step. MS (El): 274 (55) '232 (7), 195 mm, 153 (6), 135 (16), 123 (100), 11 (66), 79 (64). Isopropyl_ [2- (3-propanoyl-phenoxy) -ethyl] -amine (3) with K2C03 (14.0 kg '98 .1 mol), isopropylamine (36.2 liters' 4 5 5 · 9 mol) and water (31 liters) in a solution. The reactor was sealed and the mixture was heated to 90 ° C for 16 hours, creating a pressure of about 2 bar. The reaction mixture was allowed to cool to the soil temperature ', the aqueous phase was discarded, and the organic phase was washed with water. 0 5 M HgSO4 (aqueous solution) was added to the organic phase to bring the pH to ~ 3.5 'and then the phases were separated. The aqueous phase was stripped with fluorenyl tertiary-butadiene and used in subsequent steps. MS (El): 237 (7), 222 (34), 194⑴, 135⑺,
第13頁 436474 五、發明說明(10) 85 (80) ’72 ( 1 0 0 )NMR ( 2 0 0 MHz) : <5 7.1 (rn, 1H),6.5 (m,3H) ’4.1 (t,2H),3.9 (t,2H), 3.0 (t, 2H) ’2.9 (m,2H),1.9 (m, 2H),1.6 (m, 1H) ’1.0 (d+t,9H) 〇13C NMR (50 MHz) : (5 160.4, 160. 1,129, 8,107_ 0,l〇6‘ 6,101. 5,69. 5,67. 6, 48.5 j46.5 >23,0 >22.6 >10.5 ° 異丙基-甲基-[2-(3-丙氧基-苯氧基)—乙基]_胺(4) 添加濕10%鈀在木炭上(5. 2千克,41.1% Pd/C)與37%曱 路(20. 3升’270. 2莫耳)至3之酸性水溶液中。於3巴壓力 下使該混合物氫化約4小時。以濃N aOH處理該反應混合物 ’使pH達〜12,濾出固體,然後所形成雙相系統經EAc萃 取。分離各相’然後有機相經水洗滌,其後經濃縮。於 128-130 °C/0.3兆巴下使殘留物蒸餾,產生純異丙基-甲基 -[2-(3 -正-丙氧基苯氧基)乙基]胺(18,1千克,72.1莫耳) 〇 粗異丙基甲基-[2-(3-丙氧基-苯氧基)-乙基]胺之選用純 化反應 於環境溫度下’以3小時先後添加MeOH(9. 6升),與 1^〇4(4.85升,72.5莫耳)已溶解在^〇紅19.2升)中之溶液 至粗產物4(1 9. 0千克’ 75· 7莫耳)之醋酸乙酯溶?夜(每克粗 產物4之8毫升醋酸乙酯)中。然後經由過濾離柄所开彡成之 異丙基-曱基-[2-(3_正-丙氧基苯氧基)乙基]胺之^填$ 鹽漿體,然後該固體物質經EtOAc洗滌。在後續步驟^使 用該層析純度超過9 9%之濕產物(41. 8千克,67. /莫耳,Page 13 436474 V. Description of the invention (10) 85 (80) '72 (1 0 0) NMR (2 0 0 MHz): < 5 7.1 (rn, 1H), 6.5 (m, 3H) '4.1 (t , 2H), 3.9 (t, 2H), 3.0 (t, 2H) '2.9 (m, 2H), 1.9 (m, 2H), 1.6 (m, 1H)' 1.0 (d + t, 9H) 〇13C NMR (50 MHz): (5 160.4, 160. 1, 129, 8, 107_ 0, 106 ′ 6, 101.5, 69.5, 67.6, 48.5 j46.5 > 23,0 > 22.6 > 10.5 ° isopropyl-methyl- [2- (3-propoxy-phenoxy) -ethyl] _amine (4) add wet 10% palladium on charcoal (5.2 kg, 41.1% Pd / C) and 37% Kushiro (20.3 liters' 270. 2 moles) to an aqueous acid solution of 3. The mixture was hydrogenated at a pressure of 3 bar for about 4 hours. The reaction mixture was treated with concentrated NaOH. The pH was brought to ~ 12, the solids were filtered off, and the resulting biphasic system was extracted by EAc. The phases were separated and then the organic phase was washed with water and then concentrated. The residue was made at 128-130 ° C / 0.3 MPa Distillation yielded pure isopropyl-methyl- [2- (3--n-propoxyphenoxy) ethyl] amine (18,1 kg, 72.1 moles). Crude isopropylmethyl- [2 -(3-propoxy-phenoxy) -ethyl] amine Purify the reaction at ambient temperature 'over a period of 3 hours and add MeOH (9.6 liters), followed by a solution of 1 〇4 (4.85 liters, 72.5 mol) dissolved in ^ 0 red 19.2 liters to the crude product 4 (19.0 kg '75.7 moles) of ethyl acetate (8 ml of ethyl acetate per gram of crude product) was dissolved. The isopropyl-fluorenyl- [2- (3-n-propoxyphenoxy) ethyl] amine was then filtered through a filter to fill the salt slurry, and the solid material was then passed through EtOAc. washing. In the subsequent step ^ the wet product (41.8 kg, 67.8 / mol,
第14頁 43 64 74Page 14 43 64 74
五、發明說明(11) 89%產率)。V. Description of the invention (11) 89% yield).
熔點:131-134 °C Η3Ρ04之含量為27. 8% (w/w),其相當於$與&P0 〇 w/w理論值)之莫耳比1:1。 〆 使該產物(41. 8千克’ 67· 6莫耳)與純水(66升)混人 、 後添加漢N a Ο Η ’以使p Η達〜11 5,接著以曱基第= 取所形成之雙相混合物。分離各相,有機相"經純水萃 然後利用減壓濃縮。最後使用薄膜蒸發器除去殘留溶;^, 產生層析純度超過99%如油狀物之昱丙其_甲其: 肉氧基苯氧基)乙基]胺〇4. 28千克、,^ 6 土 _正一 MS (EI) :251 (10) -236 ( 9 ) , 80 〇〇 / iH NMR ( 40 0 MHz) : (J 7.1 … 4.0 (t,2H),3.9 (t,2H)'1;、1,)3H), (d+t, 9H)。 ,160. 1,129. 7,106. 9 54, 0,51. 7,38, 2,22. ,2.3 (S,3H) ,U (m,2H)1 U,1H) ’2.8 (ΐ,2H) 13C NMR (50 MHz) : <5 160. 3 106. 5,101· 4,69. 4,66. 8 17_ 9,10. 5。 ’ N, 5· 7 ; 0, 12. 5- 57 ; 〇, 12.73 計算值Melting point: 131-134 ° C The content of Η3Ρ04 is 27.8% (w / w), which is equivalent to a molar ratio of 1: 1 to the theoretical value of $ and & P0 w / w). 〆 Make the product (41.8 kg '67 · 6 mol) mixed with pure water (66 liters), and then add Han Na 0 Η 'to make p Η ~ 11 5 and then take 曱 基 第 = take The biphasic mixture formed. The phases were separated and the organic phase was "extracted with pure water and then concentrated under reduced pressure. Finally, a thin-film evaporator was used to remove the residual solvent; ^, which produced a chromatographic purity of more than 99%, such as oil propionate-methyl-: carboxyphenoxy) ethyl] amine 0.42 kg, ^ 6 Soil_massive MS (EI): 251 (10) -236 (9), 80 〇 / iH NMR (40 0 MHz): (J 7.1… 4.0 (t, 2H), 3.9 (t, 2H) '1 ;, 1,) 3H), (d + t, 9H). , 160. 1, 129.7, 106. 9 54, 0, 51. 7, 38, 2, 22 .., 2.3 (S, 3H), U (m, 2H) 1 U, 1H) '2.8 (ΐ, 2H) 13C NMR (50 MHz): < 5 160. 3 106. 5, 101 · 4, 69.4, 66. 8 17-9, 10.5. ’N, 5 · 7; 0, 12. 5- 57; 〇, 12.73 calculated value
實測值%:(:,71.5;11,10· % : C, 71. 67 ; H, 10. 02 ; NMeasured value%: (:, 71.5; 11, 10 ·%: C, 71. 67; H, 10. 02; N
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9704834A SE9704834D0 (en) | 1997-12-22 | 1997-12-22 | New process |
Publications (1)
Publication Number | Publication Date |
---|---|
TW436474B true TW436474B (en) | 2001-05-28 |
Family
ID=20409537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW087120435A TW436474B (en) | 1997-12-22 | 1998-12-09 | Process for the preparation of isopropyl-methyl-[2-(3-n-propoxyphenoxy)ethyl]amine |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1045826A1 (en) |
JP (1) | JP2001526253A (en) |
KR (1) | KR20010024790A (en) |
CN (1) | CN1283177A (en) |
AR (1) | AR017198A1 (en) |
AU (1) | AU1989199A (en) |
BR (1) | BR9814377A (en) |
CA (1) | CA2314988A1 (en) |
EE (1) | EE200000369A (en) |
HU (1) | HUP0100616A2 (en) |
ID (1) | ID27591A (en) |
IL (1) | IL136825A0 (en) |
IS (1) | IS5523A (en) |
NO (1) | NO20002944D0 (en) |
PL (1) | PL341438A1 (en) |
SE (1) | SE9704834D0 (en) |
SK (1) | SK8052000A3 (en) |
TR (1) | TR200001976T2 (en) |
TW (1) | TW436474B (en) |
WO (1) | WO1999032430A1 (en) |
ZA (1) | ZA9811238B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103702964A (en) * | 2011-05-26 | 2014-04-02 | 索尔维特殊聚合物意大利有限公司 | Hydro-fluorocompounds |
JP6247992B2 (en) * | 2014-04-17 | 2017-12-13 | 株式会社ダイセル | Method for producing halogen compound |
JP6635999B2 (en) * | 2017-10-13 | 2020-01-29 | 株式会社ダイセル | Method for producing potassium salt, and potassium salt |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL90704A (en) * | 1989-06-21 | 1994-10-07 | Makhteshim Chem Works Ltd | Environmentally safe method of preparing n-n-propyl-n-2-(2, 4, 6-trichlorophenoxy)-ethyl amine |
AR004691A1 (en) * | 1995-10-27 | 1999-03-10 | Astrazeneca Ab | NEW DERIVATIVES OF [3-ALCOXI-PENOXI -) - ETIL] -DIALKYLAMINE, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, THEIR USE AS LOCAL ANESTHETICS AND A PROCEDURE FOR THEIR PREPARATION |
-
1997
- 1997-12-22 SE SE9704834A patent/SE9704834D0/en unknown
-
1998
- 1998-12-08 ZA ZA9811238A patent/ZA9811238B/en unknown
- 1998-12-09 AR ARP980106239A patent/AR017198A1/en not_active Application Discontinuation
- 1998-12-09 TW TW087120435A patent/TW436474B/en not_active IP Right Cessation
- 1998-12-15 EP EP98964599A patent/EP1045826A1/en not_active Ceased
- 1998-12-15 SK SK805-2000A patent/SK8052000A3/en unknown
- 1998-12-15 IL IL13682598A patent/IL136825A0/en unknown
- 1998-12-15 JP JP2000525367A patent/JP2001526253A/en active Pending
- 1998-12-15 HU HU0100616A patent/HUP0100616A2/en unknown
- 1998-12-15 PL PL98341438A patent/PL341438A1/en not_active Application Discontinuation
- 1998-12-15 TR TR2000/01976T patent/TR200001976T2/en unknown
- 1998-12-15 EE EEP200000369A patent/EE200000369A/en unknown
- 1998-12-15 BR BR9814377-8A patent/BR9814377A/en not_active IP Right Cessation
- 1998-12-15 AU AU19891/99A patent/AU1989199A/en not_active Abandoned
- 1998-12-15 ID IDW20001192A patent/ID27591A/en unknown
- 1998-12-15 CN CN98812528A patent/CN1283177A/en active Pending
- 1998-12-15 KR KR1020007006880A patent/KR20010024790A/en not_active Application Discontinuation
- 1998-12-15 CA CA002314988A patent/CA2314988A1/en not_active Abandoned
- 1998-12-15 WO PCT/SE1998/002315 patent/WO1999032430A1/en not_active Application Discontinuation
-
2000
- 2000-06-07 IS IS5523A patent/IS5523A/en unknown
- 2000-06-08 NO NO20002944A patent/NO20002944D0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA9811238B (en) | 1999-06-22 |
NO20002944L (en) | 2000-06-08 |
SE9704834D0 (en) | 1997-12-22 |
TR200001976T2 (en) | 2000-11-21 |
NO20002944D0 (en) | 2000-06-08 |
ID27591A (en) | 2001-04-12 |
SK8052000A3 (en) | 2001-02-12 |
PL341438A1 (en) | 2001-04-09 |
BR9814377A (en) | 2000-10-10 |
CN1283177A (en) | 2001-02-07 |
EE200000369A (en) | 2001-12-17 |
WO1999032430A1 (en) | 1999-07-01 |
JP2001526253A (en) | 2001-12-18 |
CA2314988A1 (en) | 1999-07-01 |
IL136825A0 (en) | 2001-06-14 |
EP1045826A1 (en) | 2000-10-25 |
KR20010024790A (en) | 2001-03-26 |
AU1989199A (en) | 1999-07-12 |
HUP0100616A2 (en) | 2002-05-29 |
AR017198A1 (en) | 2001-08-22 |
IS5523A (en) | 2000-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6353987B2 (en) | ||
TW436474B (en) | Process for the preparation of isopropyl-methyl-[2-(3-n-propoxyphenoxy)ethyl]amine | |
JP6702623B2 (en) | Method for preparing compounds such as 3-arylbutanal useful in the synthesis of medetomidine | |
WO2007086330A1 (en) | Method for producing halogen-substituted benzenedimethanol | |
TW200408635A (en) | Optically active β-aminoketones, optically active 1, 3-amino alcohols and processes for preparing them | |
KR100625649B1 (en) | The method of preparing ?-hydroxybutyric acid alkyl esters | |
JP2002179622A (en) | Method for producing 4-acetoxystyrene | |
JP3229408B2 (en) | Process for producing novel 4-amino-5-hexenoic acid | |
JPS629098B2 (en) | ||
JP3573679B2 (en) | Polymer immobilized α-iminoester | |
KR950003328B1 (en) | 1,1-(3-ethylphenyl)phenylethylene and method for its preparation | |
JP3959178B2 (en) | Method for producing hydrazine derivative, intermediate thereof and method for producing intermediate | |
JP4018816B2 (en) | Cycloheptenone derivative and method for producing the same, and method for producing cycloheptimidazole derivative using the same | |
CN113651762B (en) | Preparation method of 1-methyl-1H-1, 2, 4-triazole-3-methyl formate | |
JP2003055285A (en) | 4-tert-BUTOXY-4'-HALOGENOBIPHENYL, METHOD FOR PRODUCING THE SAME AND METHOD FOR PRODUCING 4-HALOGENO-4'- HYDROXYBIPHENYL | |
JP3896557B2 (en) | 2'-alkyl-3'-methoxyacetophenone acetal derivative | |
JP3777407B2 (en) | Method for producing carboxylic acid derivative | |
JP4188060B2 (en) | Method for producing 1-substituted phenyl-ω-bromoalkane | |
JPH0967297A (en) | Production of bistrifluoromethylbenzoic acids | |
JP2680683B2 (en) | Method for producing solanesylamine derivative | |
JP3544694B2 (en) | Method for producing N-tert-butyl-2-piperazinecarboxamides | |
JP4263427B2 (en) | Halogeno-4-dihydroxymethylpyridine, process for producing the same and process for producing halogeno-4-pyridinecarbaldehyde using the same | |
JPS5857325A (en) | P-(3,3,3-trifluoropropyl)benzyl derivative and its production | |
JPH08225572A (en) | Improved method of massproducing bms180048 and analogue | |
JP2001072666A (en) | Production of 2-(p-alkylphenyl)pyridine compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |